Get the Stockscreener App
528.04
6.03%
30.03
Vertex Pharmaceuticals Inc stock is traded at $528.04, with a volume of 1.86M.
It is up +6.03% in the last 24 hours and up +24.22% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$498.01
Open:
$503.76
24h Volume:
1.86M
Relative Volume:
1.31
Market Cap:
$134.02B
Revenue:
$12.34B
Net Income/Loss:
$4.34B
P/E Ratio:
31.30
EPS:
16.8685
Net Cash Flow:
$3.71B
1W Performance:
+9.97%
1M Performance:
+24.22%
6M Performance:
+16.79%
1Y Performance:
+15.54%
1-Day Range:
$501.53
$529.14
1-Week Range:
$482.20
$529.14
52-Week Range:
$362.50
$529.14
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals (NASDAQ:VRTX) Gains Focus on CASGEVY Expansion - Kalkine Media
Vertex Pharmaceuticals (VRTX) Secures FDA Approval for CASGEVY i - GuruFocus
FDA approves Vertex gene therapy for children as young as 2 By Investing.com - Investing.com Canada
Vertex expands CASGEVY to U.S. children as young as 2 - Stock Titan
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia - Business Wire
Vertex Pharmaceuticals (VRTX) Gains FDA Approval for Pediatric G - GuruFocus
US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two - Reuters
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease - GlobeNewswire Inc.
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 1 July - Investing.com UK
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 1 July By Investing.com - Investing.com Canada
Joy Liu proposes multiple VRTX share sales (NASDAQ: VRTX) under restricted‑stock vesting - Stock Titan
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? - The Motley Fool
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals EVP Carmen Bozic sells $287,570 in stock - Investing.com UK
Vertex Pharmaceuticals EVP Carmen Bozic sells $287,570 in stock By Investing.com - Investing.com South Africa
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Form 4 Vertex Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Vertex (VRTX) CMO sells 596 shares under Rule 10b5-1 trading plan - Stock Titan
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech (VRTX) - Seeking Alpha
IBM, Verizon, Corning And A Health Care Stock On CNBC’s ‘Final Trades’ - Benzinga
Final trades: Vertex Pharma, Verizon, IBM and Corning - MSN
Vertex Pharma guidance and cystic fibrosis focus, shares on NASDAQ in a robust sector setup - AD HOC NEWS
Barclays Adjusts Price Target on Vertex Pharmaceuticals to $615 From $607, Maintains Overweight Rating - Moomoo
Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX) - TradingView
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Final Trades: Vertex Pharma, Verizon, IBM and Corning - CNBC
H.C. Wainwright Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $641 - Moomoo
Vertex Pharma enters Russell 1000 value, shares reflect mixed benchmark shift - AD HOC NEWS
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 1000 Value Benchmark - marketscreener.com
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 3000E Value Benchmark - marketscreener.com
Vertex Pharma analyst optimism builds ahead earnings week, shares trade near recent high - Ad-hoc-news.de
Price to book forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Price to earnings forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Vertex Pharma strategy in cystic fibrosis, shares anchored in the NASDAQ-100 healthcare field - Ad-hoc-news.de
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 26 June - Investing.com UK
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to EBIT forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Enterprise value to EBITDA forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Price to sales forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
VRTX (NASDAQ) affiliate files Form 144: 596 shares vest, multiple sales by Carmen R. Bozic - Stock Titan
Enterprise value to revenue forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Vertex Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:VRTX) - TradingView
Vertex Pharma leads biotech this week, shares hover near record highs - Ad-hoc-news.de
Fierce Biotech Layoff Tracker 2026: BioCryst ends internal programs; Biogen sheds Apellis R&D roles - Fierce Biotech
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):